Rituximab therapy for lupus nephritis: A meta‑analysis

Shen,Lei; Liu,Xiangying; Sun,Ci; Lu,Guoyuan; Zhou,Ling; Li,Jianzhong

doi:10.3892/wasj.2021.119

Rituximab therapy for lupus nephritis: A meta‑analysis

Authors:
- Lei Shen
- Xiangying Liu
- Ci Sun
- Guoyuan Lu
- Ling Zhou
- Jianzhong Li
View Affiliations

Affiliations: Department of Nephrology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, P.R. China, Department of Nephrology, Suzhou Ninth People's Hospital, Suzhou, Jiangsu 215299, P.R. China, Department of Nephrology, The Second Affiliated Hospital of Soochow University (The General Hospital of Nuclear Industry, The Sino‑France Friendship Hospital), Suzhou, Jiangsu 215004, P.R. China, Department of Nephrology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, P.R. China
Published online on: July 28, 2021 https://doi.org/10.3892/wasj.2021.119
Article Number: 48
Copyright: © Shen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to assess the clinical efficacy and safety of rituximab (RTX) therapy in the treatment of lupus nephritis by performing a meta‑analysis. For this purpose, the PubMed, Embase, Cochrane Library, Chinese Biomedical Literature, China National Knowledge Infrastructure, VIP Information and WANFANG databases were used to identify the eligible studies from January, 2000 to February, 2020. STATA16.0 and Review Manager Version 5.3 software were applied to pool the data. From the results of this search, 37 studies (30 case series and seven controlled trials) involving 1,273 patients were included. In the case series studies, the total remission (TR) rate was 81.9% (95% CI, 73.7‑88.8%) and the complete remission (CR) rate was 46.6% (95% CI, 36.4‑57.1%). Following treatment with RTX, the systemic lupus erythematosus disease activity index (SLEDAI) of patients with lupus nephritis decreased significantly [mean difference (MD), ‑8.91; 95% CI, ‑14.10 to ‑3.72, P<0.01]. The level of proteinuria also decreased significantly [standardized mean difference (SMD), ‑1.05; 95% CI, ‑1.28 to ‑0.83, P<0.01]. On the contrary, the level of serum albumin increased significantly (MD, 6.44; 95% CI, 4.42‑8.45; P<0.01). In the controlled trials, both TR and CR were significantly higher than those of the control group (TR: OR, 2.48; 95% CI, 1.58‑3.89; P<0.01; and CR: OR, 2.29; 95% CI, 1.17‑4.49; P<0.05). Compared with the control group, the SLEDAI of patients in the RTX group decreased significantly (MD, ‑3.84; 95% CI, ‑5.99 to ‑1.69; P<0.01) and the level of proteinuria in the RTX group also decreased significantly (MD, ‑1.24; 95% CI, ‑2.39 to ‑0.09; P<0.05). At the same time, the level of serum albumin increased (MD, 0.54; 95% CI, 0.22‑0.86; P<0.01). There was no difference in the relative risks of the adverse events between the two groups (OR, 0.37; P>0.05). On the whole, the findings of the present study demonstrate that RTX exhibits favorable clinical efficacy in the treatment of lupus nephritis, which can significantly reduce the level of proteinuria and SLEDAI, and increase the level of serum albumin. Compared with traditional immunosuppressive therapy (corticosteroids + cyclophosphamide and/or mycophenolate), RTX was more effective in the treatment of lupus nephritis. Additionally, rituximab exhibited good safety.

View Figures

View References

1	Gadakchi L, Hajialilo M, Nakhjavani MR, Abedi Azar S, Kolahi S, Gojazadeh M, Ebrahimi AA, Malek Mahdavi A, Noshad H and Khabbazi A: Efficacy and safety of mycophenolate mofetil versus intravenous pulse cyclophosphamide as induction therapy in proliferative lupus nephritis. Iran J Kidney Dis. 12:288–292. 2018.PubMed/NCBI
2	Jorge A, Wallace ZS, Zhang Y, Lu N, Costenbader KH and Choi HK: All-cause and cause-specific mortality trends of end-stage renal disease due to lupus nephritis from 1995 to 2014. Arthritis Rheumatol. 71:403–410. 2019.PubMed/NCBI View Article : Google Scholar
3	Tedder TF and Engel P: CD20: A regulator of cell-cycle progression of B lymphocytes. Immunol Today. 15:450–454. 1994.PubMed/NCBI View Article : Google Scholar
4	Ahuja A, Teichmann LL, Wang H, Dunn R, Kehry MR and Shlomchik MJ: An acquired defect in IgG-dependent phagocytosis explains the impairment in antibody-mediated cellular depletion in Lupus. J Immunol. 187:3888–3894. 2011.PubMed/NCBI View Article : Google Scholar
5	Schioppo T and Ingegnoli F: Current perspective on rituximab in rheumatic diseases. Drug Des Devel Ther. 11:2891–2904. 2017.PubMed/NCBI View Article : Google Scholar
6	Anderson DR, Grillo-Lo'pez A, Varns C, Chambers KS and Hanna N: Targeted anti cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C288)in the treatment of non-Hodgkin's B-cell lymphoma. Biochem Soc Trans. 25:705–708. 1997.PubMed/NCBI View Article : Google Scholar
7	Haffner D and Fischer DC: Nephrotic syndrome and rituximab: Facts and perspectives. Pediatr Nephrol. 24:1433–1438. 2009.PubMed/NCBI View Article : Google Scholar
8	Dent O: Methodological index for non-randomized studies. ANZ J Surg. 73:675–676. 2003.PubMed/NCBI View Article : Google Scholar
9	Clark HD, Wells GA, Huët C, McAlister FA, Salmi LR, Fergusson D and Laupacis A: Assessing the quality of randomized trials: Reliability of the Jadad scale. Control Clin Trials. 20:448–452. 1999.PubMed/NCBI View Article : Google Scholar
10	Boletis JN, Marinaki S, Skalioti C, Lionaki SS, Iniotaki A and Sfikakis PP: Rituximab and mycophenolate mofetil for relapsing proliferative lupus nephritis: A long-term prospective study. Nephrol Dial Transplant. 24:2157–2160. 2009.PubMed/NCBI View Article : Google Scholar
11	Chavarot N, Verhelst D, Pardon A, Caudwell V, Mercadal L, Sacchi A, Leonardi C, Le Guern V, Karras A and Daugas E: Rituximab alone as induction therapy for membranous lupus nephritis: A multicenter retrospective study. Medicine (Baltimore). 96(e7429)2017.PubMed/NCBI View Article : Google Scholar
12	Contis A, Vanquaethem H, Truchetet ME, Couzi L, Rigothier C, Richez C, Lazaro E and Duffau P: Analysis of the effectiveness and safety of rituximab in patients with refractory lupus nephritis: A chart review. Clin Rheumatol. 35:517–522. 2016.PubMed/NCBI View Article : Google Scholar
13	Davies RJ, Sangle SR, Jordan NP, Aslam L, Lewis MJ, Wedgwood R and D'Cruz DP: Rituximab in the treatment of resistant lupus nephritis: Therapy failure in rapidly progressive crescentic lupus nephritis. Lupus. 22:574–582. 2013.PubMed/NCBI View Article : Google Scholar
14	Gunnarsson I, Sundelin B, Jónsdóttir T, Jacobson SH, Henriksson EW and van Vollenhoven RF: Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum. 56:1263–1272. 2007.PubMed/NCBI View Article : Google Scholar
15	Hogan J, Godron A, Baudouin V, Kwon T, Harambat J, Deschênes G and Niel O: Combination therapy of rituximab and mycophenolate mofetil in childhood lupus nephritis. Pediatr Nephrol. 33:111–116. 2018.PubMed/NCBI View Article : Google Scholar
16	Jónsdóttir T, Zickert A, Sundelin B, Henriksson EW, van Vollenhoven RF and Gunnarsson I: Long-term follow-up in lupus nephritis patients treated with rituximab-clinical and histopathological response. Rheumatology (Oxford). 52:847–855. 2013.PubMed/NCBI View Article : Google Scholar
17	Vigna-Perez M, Hernández-Castro B, Paredes-Saharopulos O, Portales-Pérez D, Baranda L, Abud-Mendoza C and González-Amaro R: Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: A pilot study. Arthritis Res Ther. 8(R83)2006.PubMed/NCBI View Article : Google Scholar
18	Kotagiri P, Martin A, Hughes P, Becker G and Nicholls K: Single-dose rituximab in refractory lupus nephritis. Intern Med J. 46:899–901. 2016.PubMed/NCBI View Article : Google Scholar
19	Melander C, Sallée M, Trolliet P, Candon S, Belenfant X, Daugas E, Rémy P, Zarrouk V, Pillebout E, Jacquot C, et al: Rituximab in severe lupus nephritis: Early B-cell depletion affects long-term renal outcome. Clin J Am Soc Nephrol. 4:579–587. 2009.PubMed/NCBI View Article : Google Scholar
20	Pepper R, Griffith M, Kirwan C, Levy J, Taube D, Pusey C, Lightstone L and Cairns T: Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids. Nephrol Dial Transplant. 24:3717–3723. 2009.PubMed/NCBI View Article : Google Scholar
21	Sfikakis PP, Boletis JN, Lionaki S, Vigklis V, Fragiadaki KG, Iniotaki A and Moutsopoulos HM: Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: An open-label trial. Arthritis Rheum. 52:501–513. 2005.PubMed/NCBI View Article : Google Scholar
22	Iaccarino L, Bartoloni E, Carli L, Ceccarelli F, Conti F, De Vita S, Ferraccioli G, Galeazzi M, Gatto M, Gerli R, et al: Efficacy and safety of off-label use of rituximab in refractory lupus: Data from the Italian Multicentre Registry. Clin Exp Rheumatol. 33:449–456. 2015.PubMed/NCBI
23	Iwata S, Saito K, Hirata S, Ohkubo N, Nakayamada S, Nakano K, Hanami K, Kubo S, Miyagawa I, Yoshikawa M, et al: Efficacy and safety of anti-CD20 antibody rituximab for patients with refractory systemic lupus erythematosus. Lupus. 27:802–811. 2018.PubMed/NCBI View Article : Google Scholar
24	Lateef A, Lahiri M, Teng GG and Vasoo S: Use of rituximab in the treatment of refractory systemic lupus erythematosus: Singapore experience. Lupus. 19:765–770. 2010.PubMed/NCBI View Article : Google Scholar
25	Lindholm C, Börjesson-Asp K, Zendjanchi K, Sundqvist AC, Tarkowski A and Bokarewa M: Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus. J Rheumatol. 35:826–833. 2008.PubMed/NCBI
26	Ramos-Casals M, García-Hernández FJ, de Ramón E, Callejas JL, Martínez-Berriotxoa A, Pallarés L, Caminal-Montero L, Selva-O'Callaghan A, Oristrell J, Hidalgo C, et al: Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases. Clin Exp Rheumatol. 28:468–476. 2010.PubMed/NCBI
27	Arce-Salinas CA, Rodriguez-Garcia F and Gomez-Vargas JI: Long-term efficacy of anti-CD20 antibodies in refractory lupus nephritis. Rheumatol Int. 32:1245–1249. 2012.PubMed/NCBI View Article : Google Scholar
28	Catapano F, Chaudhry AN, Jones RB, Smith KG and Jayne DW: Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus. Nephrol Dial Transplant. 25:3586–3592. 2010.PubMed/NCBI View Article : Google Scholar
29	Condon MB, Ashby D, Pepper RJ, Cook HT, Levy JB, Griffith M, Cairns TD and Lightstone L: Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis. 72:1280–1286. 2013.PubMed/NCBI View Article : Google Scholar
30	Garcia-Carrasco M, Mendoza-Pinto C, Sandoval-Cruz M, Soto-Vega E, Beltran-Castillo A, Jimenez-Hernandez M, Graillet D, Gonzalez L, Rojas-Rodriguez J, Pineda-Almazana A, et al: Anti-CD20 therapy in patients with refractory systemic lupus erythematosus: A longitudinal analysis of 52 Hispanic patients. Lupus. 19:213–219. 2010.PubMed/NCBI View Article : Google Scholar
31	Bang SY, Lee CK, Kang YM, Kim HA, Suh CH, Chung WT, Park YB, Choe JY, Kim TJ, Park YW, et al: Multicenter retrospective analysis of the effectiveness and safety of rituximab in korean patients with refractory systemic lupus erythematosus. Autoimmune Dis. 2012(565039)2012.PubMed/NCBI View Article : Google Scholar
32	Tanaka Y, Takeuchi T, Miyasaka N, Sumida T, Mimori T, Koike T, Endo K, Mashino N and Yamamoto K: Efficacy and safety of rituximab in Japanese patients with systemic lupus erythematosus and lupus nephritis who are refractory to conventional therapy. Mod Rheumatol. 26:80–86. 2016.PubMed/NCBI View Article : Google Scholar
33	Tsanyan ME, Soloviev SK, Radenska-Lopovok SG, Torgashina AV, Nikolaeva EV, Khrennikov YB and Nasonov EL: Clinical and morphological improvement of lupus nephritis treated with rituximab. Folia Med (Plovdiv). 56:245–252. 2014.PubMed/NCBI View Article : Google Scholar
34	Terrier B, Amoura Z, Ravaud P, Hachulla E, Jouenne R, Combe B, Bonnet C, Cacoub P, Cantagrel A, de Bandt M, et al: Safety and efficacy of rituximab in systemic lupus erythematosus: Results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum. 62:2458–2466. 2010.PubMed/NCBI View Article : Google Scholar
35	Chen J: Clinical efficacy and safety of low-dose rituximab combined with glucocorticoid in children with lupus nephritis. J Trauma Emergency. 6:2018.
36	Qiu ML, Jin O and Fang LK: Analysis of the Effect of small dose of rituximab in the treatment of systemic lupus erythematosus. China Foreign Medical Treatment. 32:2013.
37	Su GX, Wu FQ, Wang F, Zhou ZX, Huang XL and Lu J: Rituximab therapy for severe pediatric systemic lupus erythematosus. Zhonghua Er Ke Za Zhi. 50:697–704. 2012.PubMed/NCBI(In Chinese).
38	Fan ZY, Cai YB, Gu YY, Yang CD, Bao CD and Ye S: Efficacy of rituximab in patients with refractory severe systemic lupus erythematosus. Chin Remedies Clin. 9:2009.
39	Basu B, Roy B and Babu BG: Efficacy and safety of rituximab in comparison with common induction therapies in pediatric active lupus nephritis. Pediatr Nephrol. 32:1013–1021. 2017.PubMed/NCBI View Article : Google Scholar
40	Goswami RP, Sircar G, Sit H, Ghosh A and Ghosh P: Cyclophosphamide versus mycophenolate versus rituximab in lupus nephritis remission induction: A historical Head-to-Head comparative study. J Clin Rheumatol. 25:28–35. 2019.PubMed/NCBI View Article : Google Scholar
41	Moroni G, Raffiotta F, Trezzi B, Giglio E, Mezzina N, Del Papa N, Meroni P, Messa P and Sinico AR: Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: A clinical observational study. Rheumatology (Oxford). 53:1570–1577. 2014.PubMed/NCBI View Article : Google Scholar
42	Li L, Luo FZ, Deng ZP and Wu BY: Application of rituximab in the treatment of severe and refractory lupus nephritis. J Nanjing Medical University (Natural Science edition). 34:2014.
43	Wu SH: Clinical efficacy of rituximab in the treatment of severe lupus nephritis. Road to Health. 9:2019.
44	Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, Maciuca R, Zhang D, Garg JP, Brunetta P, et al: Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study. Arthritis Rheum. 64:1215–1226. 2012.PubMed/NCBI View Article : Google Scholar
45	Zhang J, Zhao Z and Hu X: Effect of rituximab on serum levels of Anti-C1q and antineutrophil cytoplasmic autoantibodies in refractory severe lupus nephritis. Cell Biochem Biophys. 72:197–201. 2015.PubMed/NCBI View Article : Google Scholar
46	Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, Cervera R, Doria A, Gordon C, Govoni M, et al: 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 78:736–745. 2019.PubMed/NCBI View Article : Google Scholar
47	Tektonidou MG, Dasgupta A and Ward MM: Risk of End-Stage renal disease in patients with lupus nephritis, 1971-2015: A systematic review and Bayesian Meta-Analysis. Arthritis Rheumatol. 68:1432–1441. 2016.PubMed/NCBI View Article : Google Scholar
48	Yap DYH and Chan TM: B Cell abnormalities in systemic lupus erythematosus and lupus nephritis-role in pathogenesis and effect of immunosuppressive treatments. Int J Mol Sci. 20(6231)2019.PubMed/NCBI View Article : Google Scholar
49	Cassia M, Alberici F, Gallieni M and Jayne D: Lupus nephritis and B-cell targeting therapy. Expert Rev Clin Immunol. 13:951–962. 2017.PubMed/NCBI View Article : Google Scholar
50	Sun CY, Shen Y, Chen XW, Yan YC and Yang CD: Distribution and significance of B-cell infiltrates in lupus nephritis. Chin J Rheumatol. 15:2011.
51	Jónsdóttir T, Gunnarsson I, Mourão AF, Lu TY, van Vollenhoven RF and Isenberg D: Clinical improvements in proliferative vs membranous lupus nephritis following B-cell depletion: Pooled data from two cohorts. Rheumatology (Oxford). 49:1502–1504. 2010.PubMed/NCBI View Article : Google Scholar
52	Anolik JH, Campbell D, Felgar RE, Young F, Sanz I, Rosenblatt J and Looney RJ: The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum. 48:455–459. 2003.PubMed/NCBI View Article : Google Scholar
53	Alshaiki F, Obaid E, Almuallim A, Taha R, El-Haddad H and Almoallim H: Outcomes of rituximab therapy in refractory lupus: A meta-analysis. Eur J Rheumatol. 5:118–126. 2018.PubMed/NCBI View Article : Google Scholar
54	Gladman DD, Ibañez D and Urowitz MB: Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 29:288–291. 2020.PubMed/NCBI
55	Zhong Z, Li H, Zhong H and Zhou T: Clinical efficacy and safety of rituximab in lupus nephritis. Drug Des Devel Ther. 13:845–856. 2019.PubMed/NCBI View Article : Google Scholar
56	Stolyar L, Lahita RG and Panush RS: Rituximab use as induction therapy for lupus nephritis: A systematic review. Lupus. 29:892–912. 2020.PubMed/NCBI View Article : Google Scholar